The DOI matches its Crossref record; 101 of the 101 references it cites were found in a registry or an index.
Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 1×
“Multiple mechanisms of acquired clinical resistance to EGFR inhibitors in NSCLC have been identified, including emergence of the EGFR T790M resistance mutation [74, 75], loss of the activating EGFR-mutant gene [76], amplification of MET [77, 78], and hepatocyte growth factor-induced activation of MET [79].”
BackgroundEverolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Self-citationTargeting the phosphoinositide 3-kinase pathway in cancer
Liu, P., Cheng, H., Roberts, T. M., & Zhao, J. J. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2926 · Cited by 2,721
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Engelman, J. A. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2664 · Cited by 2,445
Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858 · cited 2×
“In combination with trastuzumab, the PI3K inhibitors LY294002 or Wortmannin significantly inhibited cell viability compared with either agent given alone in trastuzumab-resistant (PTEN-deficient) cell lines [26]”
BackgroundBerns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.030 · Cited by 1,627
Bean, J., Brennan, C., Shih, J.-Y., Riely, G., Viale, A., Wang, L., Chitale, D., Motoi, N., Szoke, J., Broderick, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710370104 · Cited by 1,598
The PI3K Pathway As Drug Target in Human Cancer
Courtney, K. D., Corcoran, R. B., & Engelman, J. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.3641 · Cited by 1,237
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Sergina, N. V., Rausch, M., Wang, D., Blair, J., Hann, B., Shokat, K. M., & Moasser, M. M. (2007) · Nature · doi:10.1038/nature05474 · Cited by 991
Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells
Kanzawa, T., Germano, I. M., Komata, T., Ito, H., Kondo, Y., & Kondo, S. (2004) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401359 · Cited by 986
Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)
Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D., & Pollak, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1852 · Cited by 882
Junttila, T. T., Akita, R. W., Parsons, K., Fields, C., Lewis Phillips, G. D., Friedman, L. S., Sampath, D., & Sliwkowski, M. X. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.020 · Cited by 829
FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
Turner, N., Pearson, A., Sharpe, R., Lambros, M., Geyer, F., Lopez-Garcia, M. A., Natrajan, R., Marchio, C., Iorns, E., Mackay, A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3746 · Cited by 732
Clark, A. S., West, K. A., Streicher, S. A., & Dennis, P. A. (2002) · PubMed · Cited by 665
Class I PI3K in oncogenic cellular transformation
Zhao, L., & Vogt, P. K. (2008) · Oncogene · doi:10.1038/onc.2008.244 · Cited by 594
Kosaka, T., Yatabe, Y., Endoh, H., Yoshida, K., Hida, T., Tsuboi, M., Tada, H., Kuwano, H., & Mitsudomi, T. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0714 · Cited by 589
Miller, T. W., Hennessy, B. T., González-Angulo, A. M., Fox, E. M., Mills, G. B., Chen, H., Higham, C., García-Echeverría, C., Shyr, Y., & Arteaga, C. L. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41680 · Cited by 551
Maira, S.-M., Pecchi, S., Huang, A., Burger, M., Knapp, M., Sterker, D., Schnell, C., Guthy, D., Nagel, T., Wiesmann, M., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0474 · Cited by 529
Saal, L. H., Johansson, P., Holm, K., Gruvberger-Saal, S. K., She, Q.-B., Maurer, M., Koujak, S., Ferrando, A. A., Malmström, P., Memeo, L., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702507104 · Cited by 520
Sos, M. L., Koker, M., Weir, B. A., Heynck, S., Rabinovsky, R., Zander, T., Seeger, J. M., Weiss, J., Fischer, F., Frommolt, P., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4055 · Cited by 504 · cited 1×
“PTEN loss was also found to contribute to de novo resistance to EGFR inhibitors by uncoupling EGFR with AKT-induced effectors of apoptosis in H1650 NSCLC cells [82].”
BackgroundEichhorn, P. J. A., Gili, M., Scaltriti, M., Serra, V., Guzman, M., Nijkamp, W., Beijersbergen, R. L., Valero, V., Seoane, J., Bernards, R., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1740 · Cited by 499
Ritter, C. A., Perez-Torres, M., Rinehart, C., Guix, M., Dugger, T., Engelman, J. A., & Arteaga, C. L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0701 · Cited by 497
Massarweh, S., Osborne, C. K., Creighton, C. J., Qin, L., Tsimelzon, A., Huang, S., Weiss, H., Rimawi, M., & Schiff, R. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2707 · Cited by 488
Dissecting the role of mTOR: Lessons from mTOR inhibitors
Dowling, R. J. O., Topisirovic, I., Fonseca, B. D., & Sonenberg, N. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2009.12.001 · Cited by 454
Janku, F., Wheler, J. J., Westin, S. N., Moulder, S. L., Naing, A., Tsimberidou, A. M., Fu, S., Falchook, G. S., Hong, D. S., Garrido-Laguna, I., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1196 · Cited by 447
Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer
Miller, T. W., Balko, J. M., & Arteaga, C. L. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.4879 · Cited by 413
The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas
Chakravarti, A., Zhai, G., Suzuki, Y., Sarkesh, S., Black, P. M., Muzikansky, A., & Loeffler, J. S. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.193 · Cited by 377
Loi, S., Haibe-Kains, B., Majjaj, S., Lallemand, F., Durbecq, V., Larsimont, D., Gonzalez-Angulo, A. M., Pusztai, L., Symmans, W. F., Bardelli, A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907011107 · Cited by 356
Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs
Markman, B., Dienstmann, R., & Tabernero, J. (2010) · Oncotarget · doi:10.18632/oncotarget.188 · Cited by 355
De Laurentiis, M., Arpino, G., Massarelli, E., Ruggiero, A., Carlomagno, C., Ciardiello, F., Tortora, G., D'Agostino, D., Caputo, F., Cancello, G., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2569 · Cited by 340
Hirose, Y., Berger, M. S., & Pieper, R. O. (2001) · PubMed · Cited by 333
PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors
Janku, F., Tsimberidou, A. M., Garrido-Laguna, I., Wang, X., Luthra, R., Hong, D. S., Naing, A., Falchook, G. S., Moroney, J. W., Piha-Paul, S. A., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0994 · Cited by 331
O'Brien, N. A., Browne, B. C., Chow, L., Wang, Y., Ginther, C., Arboleda, J., Duffy, M. J., Crown, J., O'Donovan, N., & Slamon, D. J. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1171 · Cited by 324
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition
Faber, A. C., Li, D., Song, Y., Liang, M.-C., Yeap, B. Y., Bronson, R. T., Lifshits, E., Chen, Z., Maira, S.-M., García-Echeverría, C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905056106 · Cited by 319
Riely, G. J., Kris, M. G., Zhao, B., Akhurst, T., Milton, D. T., Moore, E., Tyson, L., Pao, W., Rizvi, N. A., Schwartz, L. H., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0560 · Cited by 287
Acquired resistance to tyrosine kinase inhibitors during cancer therapy
Engelman, J. A., & Settleman, J. (2008) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2008.01.004 · Cited by 284
Fedele, C. G., Ooms, L. M., Ho, M., Vieusseux, J., O'Toole, S. A., Millar, E. K., Lopez-Knowles, E., Sriratana, A., Gurung, R., Baglietto, L., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015245107 · Cited by 283
Ihle, N. T., Lemos, R., Wipf, P., Yacoub, A., Mitchell, C., Siwak, D., Mills, G. B., Dent, P., Kirkpatrick, D. L., & Powis, G. (2009) · Cancer Research · doi:10.1158/0008-5472.can-07-6656 · Cited by 274
Creighton, C. J., Fu, X., Hennessy, B. T., Casa, A. J., Zhang, Y., Gonzalez-Angulo, A. M., Lluch, A., Gray, J. W., Brown, P. H., Hilsenbeck, S. G., et al. (2010) · Breast Cancer Research · doi:10.1186/bcr2594 · Cited by 258
O'Brien, C., Wallin, J. J., Sampath, D., GuhaThakurta, D., Savage, H., Punnoose, E. A., Guan, J., Berry, L., Prior, W. W., Amler, L. C., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2828 · Cited by 255
Arpino, G., Green, S. J., Allred, D. C., Lew, D., Martino, S., Osborne, C. K., & Elledge, R. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0110 · Cited by 255
Fan, M., Yan, P. S., Hartman-Frey, C., Chen, L., Paik, H., Oyer, S. L., Salisbury, J. D., Cheng, A. S. L., Li, L., Abbosh, P. H., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1666 · Cited by 248
Arribas, J., Baselga, J., Pedersen, K., & Parra-Palau, J. L. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3795 · Cited by 236
Cui, X., Zhang, P., Deng, W., Oesterreich, S., Lu, Y., Mills, G. B., & Lee, A. V. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0318 · Cited by 233
Kataoka, Y., Mukohara, T., Shimada, H., Saijo, N., Hirai, M., & Minami, H. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp304 · Cited by 231
Gallardo, A., Lerma, E., Escuin, D., Tibau, A., Muñoz, J., Ojeda, B., Barnadas, A., Adrover, E., Sánchez-Tejada, L., Giner, D., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.85 · Cited by 230
Kao, G. D., Jiang, Z., Fernandes, A. M., Gupta, A. K., & Maity, A. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703042200 · Cited by 228
p95HER-2 Predicts Worse Outcome in Patients with HER-2-Positive Breast Cancer
Sáez, R., Molina, M. A., Ramsey, E. E., Rojo, F., Keenan, E. J., Albanell, J., Lluch, A., García-Conde, J., Baselga, J., & Clinton, G. M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1807 · Cited by 218
Morrow, P. K., Wulf, G. M., Ensor, J., Booser, D. J., Moore, J. A., Flores, P. R., Xiong, Y., Zhang, S., Krop, I. E., Winer, E. P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2321 · Cited by 209 · cited 1×
“The study showed encouraging antitumor activity, which was further corroborated by a pooled analysis of two Phase I/II studies (N = 47) [45].”
ResultAndre, F., Campone, M., O'Regan, R., Manlius, C., Massacesi, C., Tarek, S., Mukhopadhyay, P., Soria, J.-C., Naughton, M., & Hurvitz, S. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.8549 · Cited by 207
Tazzari, P. L., Cappellini, A., Ricci, F., Evangelisti, C., Papa, V, Grafone, T., Martinelli, G., Conte, R., Cocco, L., McCubrey, J. A., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404523 · Cited by 196
Treatment of advanced non small cell lung cancer.
Bareschino, M. A., Schettino, C., Rossi, A., Maione, P., Sacco, P. C., Zeppa, R., & Gridelli, C. (2011) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2010.12.08 · Cited by 186
Targeting the Phosphatidylinositol 3-Kinase Signaling Pathway in Breast Cancer
Hernandez-Aya, L. F., & Gonzalez-Angulo, A. M. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0402 · Cited by 177
Ellis, M. J., Tao, Y., Young, O., White, S., Proia, A. D., Murray, J., Renshaw, L., Faratian, D., Thomas, J., Dowsett, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.3034 · Cited by 173
García-García, C., Ibrahim, Y. H., Serra, V., Calvo, M. T., Guzmán, M., Grueso, J., Aura, C. M., Pérez-García, J. M., Jessen, K., Liu, Y., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2750 · Cited by 168
Prasad, G., Sottero, T. L., Yang, X., Mueller, S., James, C. D., Weiss, W. A., Polley, M. Y., Ozawa, T., Berger, M. S., Aftab, D. T., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq193 · Cited by 165
Hirose, Y., Katayama, M., Mirzoeva, O. K., Berger, M. S., & Pieper, R. O. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2633 · Cited by 164
PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib
Wang, L., Zhang, Q., Zhang, J., Sun, S., Guo, H., Jia, Z. Y., Wang, B., Shao, Z., Wang, Z., & Hu, X. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-248 · Cited by 162
Frogne, T., Benjaminsen, R. V., Sonne‐Hansen, K., Sørensen, B. S., Nexø, E., Lænkholm, A., Rasmussen, L. M., Riese, D. J., de Crémoux, P., Stenvang, J., et al. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0011-8 · Cited by 157
Opel, D., Westhoff, M., Bender, A., Braun, V., Debatin, K., & Fulda, S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6769 · Cited by 155
Kosaka, T., Yamaki, E., Mogi, A., & Kuwano, H. (2011) · BioMed Research International · doi:10.1155/2011/165214 · Cited by 146
Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment.
Stein, R. C. (2001) · Endocrine Related Cancer · doi:10.1677/erc.0.0080237 · Cited by 145
Davis, J. M., Navolanic, P. M., Oppenheimer, C. W., Steelman, L. S., Hu, W., Konopleva, M. Y., Blagosklonny, M. V., & McCubrey, J. A. (2003) · PubMed · Cited by 145
Reduced PTEN expression predicts relapse in patients with breast carcinoma treated by tamoxifen
Shoman, N. M., Klassen, S., McFadden, A., Bickis, M., Torlakovic, E., & Chibbar, R. (2004) · Modern Pathology · doi:10.1038/modpathol.3800296 · Cited by 142
Ellis, M. J., Li, L., Crowder, R. J., Yu, T., Hoog, J., Snider, J., Davies, S. R., DeSchryver, K., Evans, D. B., Steinseifer, J., et al. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0575-y · Cited by 140
Kokubo, Y., Gemma, A., Noro, R., Seike, M., Kataoka, K., Matsuda, K., Okano, T., Minegishi, Y., Yoshimura, A., Shibuya, M., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602559 · Cited by 137
Chemically targeting the PI3K family
Knight, Z. A., & Shokat, K. M. (2007) · Biochemical Society Transactions · doi:10.1042/bst0350245 · Cited by 134
Ghayad, S. E., Vendrell, J. A., Larbi, S. B., Dumontet, C., Bièche, I., & Cohen, P. A. (2009) · International Journal of Cancer · doi:10.1002/ijc.24750 · Cited by 131
Donev, I. S., Wang, W., Yamada, T., Li, Q., Takeuchi, S., Matsumoto, K., Yamori, T., Nishioka, Y., Sone, S., & Yano, S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1993 · Cited by 119
Prevo, R., Deutsch, É., Sampson, O. L., Diplexcito, J., Cengel, K. A., Harper, J. V., O’Neill, P., McKenna, W. G., Patel, S. K., & Bernhard, E. J. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0757 · Cited by 118
Nahta, R., & O'Regan, R. M. (2010) · Clinical Breast Cancer · doi:10.3816/cbc.2010.s.015 · Cited by 97
Cavazzoni, A., Bonelli, M. A., Fumarola, C., Monica, S. L., Airoud, K., Bertoni, R., Alfieri, R. R., Galetti, M., Tramonti, S., Galvani, E., et al. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.03.034 · Cited by 94
Leung, E. Y., Kim, J. E., Rewcastle, G. W., Finlay, G. J., & Baguley, B. C. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.11.15527 · Cited by 88
Pancholi, S., Lykkesfeldt, A., Hilmi, C., Banerjee, S. N., Leary, A. F., Drury, S. C., Johnston, S. R. D., Dowsett, M., & Martin, L. (2008) · Endocrine Related Cancer · doi:10.1677/erc-07-0240 · Cited by 88
Caporali, S., Levati, L., Starace, G., Ragone, G., Bonmassar, E., Alvino, E., & D’Atri, S. (2008) · Molecular Pharmacology · doi:10.1124/mol.107.044743 · Cited by 87
Sarkaria, J. N., Galanis, E., Wu, W., Peller, P. J., Giannini, C., Brown, P. D., Uhm, J. H., McGraw, S. C., Jaeckle, K. A., & Buckner, J. C. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.05.064 · Cited by 85
Li, H., Schmid‐Bindert, G., Wang, D., Zhao, Y. F., Yang, X., Su, B., & Zhou, C. (2011) · Advances in Medical Sciences · doi:10.2478/v10039-011-0043-x · Cited by 85
Involvement of Akt-1 and mTOR in Sensitivity of Breast Cancer to Targeted Therapy
Sokolosky, M. L., Stadelman, K. M., Chappell, W. H., Abrams, S. L., Martelli, A. M., Stivala, F., Libra, M., Nicoletti, F., Дробот, Л. Б., Franklin, R. A., et al. (2011) · Oncotarget · doi:10.18632/oncotarget.302 · Cited by 84
Lee, Y. J., Cho, B. C., Jee, S. H., Moon, J. W., Kim, S. I., Chang, J., Chung, K. S., Park, I. K., Choi, S. H., & Kim, J.-H. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.5480 · Cited by 83
Ghayad, S. E., Bièche, I., Vendrell, J. A., Keime, C., Lidereau, R., Dumontet, C., & Cohen, P. A. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00955.x · Cited by 82
Sarkaria, J. N., Galanis, E., Wu, W., Dietz, A. B., Kaufmann, T. J., Gustafson, M. P., Brown, P. D., Uhm, J. H., Rao, R. D., Doyle, L. A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1453 · Cited by 79
Takeuchi, S., Wang, W., Li, Q., Yamada, T., Kita, K., Donev, I. S., Nakamura, T., Matsumoto, K., Shimizu, E., Nishioka, Y., et al. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.05.023 · Cited by 78
The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis
Harris, C. A., Ward, R. L., Dobbins, T., Drew, A. K., & Pearson, S. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq593 · Cited by 78
Tabara, K., Kanda, R., Sonoda, K., Kubo, T., Murakami, Y., Kawahara, A., Azuma, K., Abe, H., Kage, M., Yoshinaga, A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041017 · Cited by 75
Barone, I., Cui, Y., Herynk, M. H., Corona‐Rodriguez, A., Giordano, C., Selever, J., Beyer, A. R., Andò, S., & Fuqua, S. A. W. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4194 · Cited by 71
Effect of temozolomide on the U-118 glioma cell line
do Carmo, A., Carvalheiro, H., Crespo, I., Nunes‐Correia, I., & Lopes, M. C. (2011) · Oncology Letters · doi:10.3892/ol.2011.406 · Cited by 67
Chen, Z., Aoki, S., Komatsu, M., Ueda, K., Sumizawa, T., Furukawa, T., Okumura, H., Ren, X., Belinsky, M. G., Lee, K., et al. (2001) · International Journal of Cancer · doi:10.1002/ijc.1290 · Cited by 63
Chen, J. S., Zhou, L. J., Entin‐Meer, M., Yang, X., Donker, M., Knight, Z. A., Weiss, W. A., Shokat, K. M., Haas-Kogan, D. A., & Stokoe, D. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0393 · Cited by 63
Brünner-Kubath, C., Shabbir, W., Saferding, V., Wagner, R., Singer, C. F., Valent, P., Berger, W., Marian, B., Zielinski, C. C., Grusch, M., et al. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1232-1 · Cited by 62
Kim, S. M., Kim, J. S., Kim, J.-H., Yun, C., Kim, E. M., Kim, H. K., Solca, F., Choi, S.-Y., & Cho, B. C. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.04.006 · Cited by 61
Gayle, S. S., Arnold, S. L. M., O'Regan, R. M., & Nahta, R. (2012) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152012799015002 · Cited by 51
Tumor Genetic Testing for Patient Selection in Phase I Clinical Trials: The Case of PI3K Inhibitors
Juric, D., & Baselga, J. M. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.6390 · Cited by 43
LY294002 enhances cytotoxicity of temozolomide in glioma by down-regulation of the PI3K/Akt pathway
Jiang, C. (2011) · Molecular Medicine Reports · doi:10.3892/mmr.2011.674 · Cited by 39
Isoyama, S., Dan, S., Nishimura, Y. H., Nakamura, N., Kajiwara, G., Seki, M., Irimura, T., & Yamori, T. (2012) · Cancer Science · doi:10.1111/cas.12004 · Cited by 25
Advances with phospholipid signalling as a target for anticancer drug development.
Powis, G., Berggren, M. I., Gallegos, A. C., Frew, T., Hill, S., Kozikowski, A. P., Bonjouklian, R., Zalkow, L. H., Abraham, R. T., & Ashendel, C. L. (1995) · Acta Biochimica Polonica · doi:10.18388/abp.1995_4893 · Cited by 18
Abstract 3608: PTEN mutation associated with EGFR TKI de novo resistance
Kim, Y.-W., Ko, J., Cui, Z., Ahn, M., & Park, K. (2010) · Cancer Research · doi:10.1158/1538-7445.am10-3608 · Cited by 1
Cited by
Targeting PI3K/Akt signal transduction for cancer therapy
He, Y., Sun, M. M., Zhang, G. G., Yang, J., Chen, K. S., Xu, W. W., & Li, B. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00828-5 · Cited by 1,892
Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway
Polivka, J., & Janku, F. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.004 · Cited by 765
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer
Yu, L., Wei, J., & Liu, P. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.019 · Cited by 763
Tewari, D., Patni, P., Bishayee, A., Sah, A. N., & Bishayee, A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.008 · Cited by 642
PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
Li, X., Wu, C., Chen, N., Gu, H., Yen, A., Cao, L., Wang, E., & Wang, L. (2016) · Oncotarget · doi:10.18632/oncotarget.7961 · Cited by 542
Metadata
- Authors
- Burris, H. A.
- Venue
- Cancer Chemotherapy and Pharmacology
- Published
- 2013-02-03
- Volume
- 71
- Issue
- 4
- Pages
- 829-842
- ISSN
- 0344-5704 (ISSN-L)
- 1432-0843
- OpenAlex
- W2151010413
- Cited by
- 440
- References
- 101
- FWCI
- 20.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.